Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis

Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis Key PointsQuestionIs the risk of serious infections different between biologic or targeted exposures in patients with psoriasis? FindingsIn this cohort study of 44 239 new users of biologics, the risk of serious infections was higher for new users of adalimumab or infliximab vs etanercept, whereas ustekinumab was associated with a lower risk of a serious infection. Risk of serious infections was not increased for new users of secukinumab, ixekizumab, brodalumab, guselkumab, or apremilast vs etanercept, but the risk of serious infections was increased with the use of concomitant nonsteroidal anti-inflammatory drugs or systemic corticosteroids. MeaningThese results could help physicians choose a biologic for patients with psoriasis who are at risk of serious infections. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis

Loading next page...
 
/lp/american-medical-association/association-between-biologics-use-and-risk-of-serious-infection-in-exICEmn0sO
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/jamadermatol.2021.2599
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionIs the risk of serious infections different between biologic or targeted exposures in patients with psoriasis? FindingsIn this cohort study of 44 239 new users of biologics, the risk of serious infections was higher for new users of adalimumab or infliximab vs etanercept, whereas ustekinumab was associated with a lower risk of a serious infection. Risk of serious infections was not increased for new users of secukinumab, ixekizumab, brodalumab, guselkumab, or apremilast vs etanercept, but the risk of serious infections was increased with the use of concomitant nonsteroidal anti-inflammatory drugs or systemic corticosteroids. MeaningThese results could help physicians choose a biologic for patients with psoriasis who are at risk of serious infections.

Journal

JAMA DermatologyAmerican Medical Association

Published: Sep 21, 2021

References